White House Reiterates Confidence In FDA Expertise, Independence With J&J Vaccine Pause
Not only did White House and other officials support the recommendation, but also made clear they had no advance notice of it.
You may also be interested in...
Unlike its response to incidents of blood clots with J&J’s vaccine, the US FDA is not calling for a pause in its administration following reports of about 100 cases of Guillain-Barré syndrome. CDC advisory panel is to discuss the issue at an upcoming meeting.
Public confidence in the Johnson & Johnson vaccine may be shaken. But faith in the regulatory system is solid, according to a recent poll, an Administration official maintained.
US FDA’s Search For Class-Wide Vaccine Blood-Clot Effect Makes Scientific Sense, But Raises Questions
Several adenovirus vaccine developers say the products cannot be compared, potentially complicating the US FDA and CDC’s decision on ending the recommended pause in the use of Janssen’s vaccine.